Nurix Therapeutics (NRIX) CLO share sale tied to RSU tax withholding
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. reported insider activity by Chief Legal Officer Christine Ring on July 30, 2026. Three RSU tranches of 3,750, 2,858, and 3,572 units (total 10,180) vested and converted into the same number of common shares at a $0.00 exercise price. On the same date, 3,847 common shares were sold at a weighted average price of $23.3828 per share to cover tax withholding obligations through a mandatory “sell to cover” mechanism under the issuer’s equity plans, and the filing notes these were not discretionary trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Ring Christine
Role
Chief Legal Officer
Sold
3,847 shs ($90K)
Approx. gross sale proceeds
$90K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F4, F5 | 3,750 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F6, F5 | 2,858 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F7, F5 | 3,572 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,858 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,572 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2 | 3,847 | $23.3828 | $90K |
Holdings After Transaction:
Restricted Stock Units — 70,562 shares (Direct);
Common Stock — 19,912 shares (Direct)
Footnotes (7)
- F1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F4. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F5. RSUs do not expire; they either vest or are canceled prior to the vest date.
- F6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Key Figures
Common shares sold: 3,847 shares
Weighted average sale price: $23.3828 per share
RSUs converted (tranche 1): 3,750 shares
+3 more
6 metrics
Common shares sold
3,847 shares
Common stock sold on July 30, 2026 to cover tax withholding
Weighted average sale price
$23.3828 per share
Price for 3,847 common shares sold; range $23.00–$23.90
RSUs converted (tranche 1)
3,750 shares
RSUs vesting quarterly over three years from initial vest date July 30, 2024
RSUs converted (tranche 2)
2,858 shares
RSUs vesting quarterly over three years from initial vest date July 30, 2025
RSUs converted (tranche 3)
3,572 shares
RSUs vesting quarterly over three years from initial vest date July 30, 2026
Total RSUs converted
10,180 shares
Sum of three RSU tranches (3,750; 2,858; 3,572) exercised on July 30, 2026
Key Terms
Restricted Stock Units, sell to cover, weighted average sale price
3 terms
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at which shares were sold"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Nurix Therapeutics (NRIX) report for Christine Ring?
Nurix Therapeutics reported that Chief Legal Officer Christine Ring had 10,180 RSUs vest and convert into common stock, and 3,847 common shares were sold on July 30, 2026 to satisfy tax withholding obligations via a mandatory “sell to cover” arrangement.
What RSU awards vested for Nurix Therapeutics (NRIX) Chief Legal Officer on July 30, 2026?
On July 30, 2026, three RSU awards vested for Christine Ring, converting 3,750, 2,858, and 3,572 restricted stock units into the same number of common shares. Each RSU represents a contingent right to receive one share of Nurix Therapeutics common stock upon vesting.
How are Christine Ring’s RSUs at Nurix Therapeutics (NRIX) structured to vest?
Footnotes explain that each RSU grant vests as to 1/12 of the total award quarterly over three years, with first vesting dates on July 30 of 2024, 2025, or 2026, respectively, subject to her continued service, after which common shares are delivered.